Aktienanalyse wird geladen …
EW · NYSE · Medical Devices · USA
85,71 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 6,07 Mrd. | 1,07 Mrd. | 1,83 $ | 585,8 Mio. | 1,8 Mio · 0,3 % | 15,3 Mio · 2,6 % | 78 % | 17,7 % | 2,28 $ | 0,27 $ | — |
| 2024 | 5,44 Mrd. | 4,17 Mrd. | 6,97 $ | 599,3 Mio. | 1,9 Mio · 0,3 % | 12 Mio · 2 % | 79,5 % | 76,8 % | 0,48 $ | 0,27 $ | — |
| 2023 | 5,01 Mrd. | 1,4 Mrd. | 2,30 $ | 609,4 Mio. | 1,6 Mio · 0,3 % | 16,4 Mio · 2,7 % | 80,5 % | 28 % | 1,05 $ | 0,23 $ | — |
| 2022 | 4,46 Mrd. | 1,52 Mrd. | 2,44 $ | 624,2 Mio. | 1,5 Mio · 0,2 % | 8,5 Mio · 1,4 % | 83,8 % | 34,1 % | 1,56 $ | 0,20 $ | — |
| 2021 | 5,23 Mrd. | 1,5 Mrd. | 2,38 $ | 631,2 Mio. | 1,3 Mio · 0,2 % | 2 Mio · 0,3 % | 76,1 % | 28,7 % | 2,23 $ | 0,17 $ | — |
| 2020 | 4,39 Mrd. | 823,4 Mio. | 1,30 $ | 631,9 Mio. | 1,1 Mio · 0,2 % | 5,9 Mio · 0,9 % | 75,4 % | 18,8 % | 1,02 $ | 0,15 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,74 Mrd. | 241,9 Mio. | 0,42 $ | 577,6 Mio. | 77,5 % | 13,9 % | 1,01 $ |
| Q1 2026 | 1,65 Mrd. | 380,7 Mio. | 0,66 $ | 580,7 Mio. | 78 % | 23,1 % | -0,04 $ |
| Q4 2025 | 1,57 Mrd. | 91,2 Mio. | 0,16 $ | 581,8 Mio. | 78,2 % | 5,8 % | 0,60 $ |
| Q3 2025 | 1,55 Mrd. | 291,1 Mio. | 0,50 $ | 585,7 Mio. | 77,8 % | 18,7 % | 0,88 $ |
| Q2 2025 | 1,53 Mrd. | 333,2 Mio. | 0,57 $ | 587,9 Mio. | 77,5 % | 21,8 % | 0,41 $ |
| Q1 2025 | 1,41 Mrd. | 358 Mio. | 0,61 $ | 587,8 Mio. | 78,7 % | 25,3 % | 0,38 $ |
| Q4 2024 | 1,39 Mrd. | 385,6 Mio. | 0,66 $ | — | 78,9 % | 27,8 % | -0,30 $ |
| Q3 2024 | 1,35 Mrd. | 3,07 Mrd. | 5,13 $ | 598,1 Mio. | 80,6 % | 226,7 % | 0,50 $ |
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
CMS expands TAVR Medicare coverage to asymptomatic patients
Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
Edwards Lifesciences Comments on TAVR National Coverage Decision
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest EW und jede andere Aktie unbegrenzt.